The Additional Six-membered Hetero Ring Is One Of The Cyclos In A Tricyclo Ring System Patents (Class 544/126)
-
Publication number: 20040116405Abstract: A compound of formula (I): or a salt, solvate or physiologically functional derivative thereof for use as a IK and/or SK channel opener. Methods of screening SK ion channels, particularly SK1 and medicaments for the treatment of a urinogenital, respiratory, cardiovascular, neuronal disorder, of sleeping disorders, sickle cell anemia, pain, inflammation and bowel disease (IBD) are also disclosed.Type: ApplicationFiled: December 16, 2003Publication date: June 17, 2004Inventors: Brian Cox, Jennifer Elizabeth Cryan, Timothy James Dale, Graeme Michael Robertson, Derek John Trezise
-
Patent number: 6743794Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).Type: GrantFiled: May 21, 2002Date of Patent: June 1, 2004Assignee: Eli Lilly and CompanyInventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst, Qiupang Wang
-
Patent number: 6730671Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes, for making such novel compounds.Type: GrantFiled: February 13, 2003Date of Patent: May 4, 2004Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Charles L. Cywin, Michel J. Emmanuel, Tina Morwick, Denice M. Spero, David S. Thomson, Yancey D. Ward
-
Publication number: 20040082575Abstract: Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-&bgr; over ER-&agr;. Methods are disclosed for modulating ER-&bgr; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially ER-&bgr;. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natureal hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.Type: ApplicationFiled: May 7, 2003Publication date: April 29, 2004Applicant: Signal Pharmaceuticals, Inc.Inventors: Shripad S. Bhagwat, Leah Marie Gayo-Fung, Bernd M. Stein, Qi Chao, Anthony R. Gangloff, Jeffrey A. McKie, Kenneth D. Rice
-
Publication number: 20040082578Abstract: This invention provides novel arylindenopyridines of the formula: 1Type: ApplicationFiled: September 27, 2002Publication date: April 29, 2004Inventors: Geoffrey R. Heintzelman, Kristin M. Averill, John H. Dodd, Keith T. Demarest, Yuting Tang, Paul F. Jackson
-
Patent number: 6723733Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.Type: GrantFiled: May 15, 2001Date of Patent: April 20, 2004Assignee: Guilford Pharmaceuticals, Inc.Inventors: Jia-He Li, Vincent J. Kalish, Jie Zhang, Larisa E. Serdyuk, Dana Victor Ferraris, Ge Xiao, Paul W. Kletzly
-
Patent number: 6720319Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.Type: GrantFiled: October 1, 2002Date of Patent: April 13, 2004Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Weimin Liu, Denice M. Spero, David S. Thomson, Yancey D. Ward, Erick R. R. Young
-
Publication number: 20040063700Abstract: 1Type: ApplicationFiled: July 8, 2003Publication date: April 1, 2004Inventors: Peter T.W. Cheng, Sean Chen, Pratik Devasthale, Charles Z. Ding, Timothy F. Herpin, Shung Wu, Hao Zhang, Wei Wang, Xiang-Yang Ye
-
Publication number: 20040043988Abstract: The present invention relates to a class of compounds represented by the Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the &agr;v&bgr;3 and/or &agr;v &bgr;5 integrin.Type: ApplicationFiled: August 21, 2003Publication date: March 4, 2004Inventors: Ish Kurmar Khanna, Michael Clare, Alan Gasiecki, Thomas Rogers, Barbara B. Chen, Mark Russell, Hwang-Fun Lu
-
Publication number: 20040038970Abstract: The present invention is directed to compounds of formula (I) wherein the variables are defined in the specification, which bind to somatostatin receptors and block Na channels.Type: ApplicationFiled: March 7, 2003Publication date: February 26, 2004Applicant: Societe de Conseils de Recherches etd' Application Scientifiques, S.A.S. a Paris, France corp.Inventors: Christophe Alain Thurieau, Lydie Francine Poitout, Marie-Odile Galcera, Christophe Philippe Moinet, Thomas D. Gordon, Barry A. Morgan, Dennis C. H. Bigg, Jacques Pommier
-
Publication number: 20040038967Abstract: An objective of the present invention is to provide carbapenem derivatives which have strong antibiotic activity also against MRSA, PRSP, Influenzavirus, and &bgr;-lactamase producing bacteria and are stable to DHP-1.Type: ApplicationFiled: February 14, 2003Publication date: February 26, 2004Inventors: Yuko Kano, Yasuo Yamamoto, Takahisa Maruyama, Takehiko Sawabe, Eiki Shitara, Kazuhiro Aihara, Kunio Atsumi, Takashi Ida
-
Patent number: 6696461Abstract: Compounds of formula (I) in which the substituents as defined in the description are useful for preventing and treating gastrointestinal disorders.Type: GrantFiled: October 4, 2002Date of Patent: February 24, 2004Assignee: Altana Pharma AGInventors: Jörg Senn-Bilfinger, Wilm Buhr, Reinhard Huber, Ernst Sturm
-
Patent number: 6693111Abstract: Indole-2,3-dione-3-oxime derivatives, for instance compounds represented by the formula are capable of antagonizing the effect of excitatory amino acids, such as glutamate. Also disclosed are methods of preparing the compounds, pharmaceutical compositions comprising them, and methods of treatment of disorders or diseases which are responsive to excitatory amino acid receptor antagonists.Type: GrantFiled: May 31, 2000Date of Patent: February 17, 2004Assignee: NeuroSearch A/SInventors: Frank Watjen, Jorgen Drejer
-
Patent number: 6693198Abstract: Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): R1 is —(CH2)nN+HR3R4 X− or R1 is —(CH2)nN+HR3R4 X− or —(CH2)nNR3R4 when R2 is —N+HR6R7. R2 is —OR5, halogen, —NR6R7, —N+HR6R7 X− sulphonic acid, nitro, —NR5COOR5, —NR5COR5 or —OCOR5; R3 and R4 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; each R5 is independently —H or a C1-C4 alkyl group; R6 and R7 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; n is an integer from 0-3; and X− is the carboxylate anion of an organic carboxylic acid compound. Also disclosed are methods of preparing certain compounds represented by Structural Formula (I).Type: GrantFiled: April 22, 2002Date of Patent: February 17, 2004Assignee: Xanthus Life Sciences, Inc.Inventors: Alfred M. Ajami, David O. Barlow
-
Publication number: 20040029877Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: ApplicationFiled: December 21, 2001Publication date: February 12, 2004Inventors: Stephen L. Crooks, Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
-
Publication number: 20040029876Abstract: This invention relates to novel acylamino cyclopropane derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as modulators of dopamine D3 receptors and for the treatment of anxiety, psychosis, substance abuse, Parkinson's disease, sexual dysfunction, and other central nervous system disorders.Type: ApplicationFiled: July 29, 2003Publication date: February 12, 2004Applicant: Pfizer IncInventors: Anton F. J. Fliri, Anthony R. Reinhold
-
Publication number: 20040023955Abstract: The present invention relates to tricyclic 2-pyridone compounds of formula (I): 1Type: ApplicationFiled: June 10, 2003Publication date: February 5, 2004Inventors: James D. Rodgers, Haisheng Wang, Mona Patel, Argyrios Arvanitis, Anthony J. Cocuzza
-
Patent number: 6686373Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof wherein the dashed lines represent optional double bonds; C1, C2, C3 and C4 are carbon atom; R1 is C1-4 alkyl; R2 is H, amino, etc.; R3 is H, halo-CH2—, C2-8 alkyl or Q1-, wherein said C2-8 alkyl is optionally substituted with up to 3 substituents selected from halo, C1-3 alkyl, R4(R5)N, etc.; R4 is H, C1-7 alkyl, etc.; R5 is H, C1-7alkyl, etc.; R6 and R7 are independently selected from H and C1-4 alkyl; R8 is aryl or heteroaryl; Q1 is a 4-12 membered monocyclic or bicyclic aromatic, partially saturated or fully saturated ring optionally containing up to 4 heteroatoms selected from O, N and S, and is optionally substituted with halo, C1-4 alkyl, etc.; Y5, Y6, Y7 and Y8 are hydrogen; Y1, Y2, Y3 and Y4 are independently selected from hydrogen, halo, etc.Type: GrantFiled: July 9, 2002Date of Patent: February 3, 2004Assignee: Warner-Lambert Company LLCInventors: Kiyoshi Kawamura, Sachiko Mihara, Seiji Nukui, Chikara Uchida
-
Patent number: 6686472Abstract: Methods of preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce the biosynthesis of various cytokines including interferon, and they inhibit tumor formation in animal models.Type: GrantFiled: May 13, 2003Date of Patent: February 3, 2004Assignee: 3M Innovative Properties CompanyInventors: John F. Gerster, Stephen L. Crooks, Kyle J. Lindstrom
-
Publication number: 20040019048Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: ApplicationFiled: February 20, 2003Publication date: January 29, 2004Applicant: 3M Innovative Properties CompanyInventors: Stephen L. Crooks, George W. Griesgraber, Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
-
Patent number: 6683181Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.Type: GrantFiled: November 5, 2002Date of Patent: January 27, 2004Assignee: Pharmacia and Upjohn ComapnyInventors: Valerie A. Vaillancourt, Sandra Staley, Audris Huang, Richard Allen Nugent, Ke Chen, Sajiv K. Nair, James A. Nieman, Joseph Walter Strohbach
-
Patent number: 6683079Abstract: 3-(amino- or aminoalkyl) pyridinone derivatives having the formula (1) wherein Q, X, Y, and R3-R6 are as defined, which derivatives are useful for the treatment of HIV related diseases.Type: GrantFiled: July 15, 2002Date of Patent: January 27, 2004Assignees: Centre National de la Recherche Scientifique, Insitut CurieInventors: Emile Bisagni, Valerie Dolle, Chi Hung Nguyen, Claude Monneret, David Grierson, Anne-Marie Aubertin
-
Publication number: 20040014754Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: ApplicationFiled: January 28, 2003Publication date: January 22, 2004Applicant: 3M Innovative Properties CompanyInventors: Stephen L. Crooks, Bryon A. Merrill, Michael J. Rice
-
Patent number: 6677334Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.Type: GrantFiled: September 12, 2002Date of Patent: January 13, 2004Assignee: 3M Innovative Properties CompanyInventors: John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
-
Publication number: 20040006079Abstract: The invention relates to novel 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives of the formula (I) and (IV): 1Type: ApplicationFiled: June 17, 2003Publication date: January 8, 2004Inventors: Weiqin Jiang, Zhihua Sui
-
Publication number: 20040002604Abstract: Substituted phenylalkynes of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.Type: ApplicationFiled: June 17, 2003Publication date: January 1, 2004Inventors: Richard Apodaca, Xiaohu Deng, Jill A. Jablonowski, Neelakandha Mani, Chennagiri R. Pandit, Wei Xiao
-
Patent number: 6670373Abstract: The present invention relates to a compound of formula (I), which is useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.Type: GrantFiled: July 2, 2002Date of Patent: December 30, 2003Assignee: Eli Lilly and CompanyInventors: Rosanne Bonjouklian, Douglas Webb Johnson, Peter Ambrose Lander, Mark Christopher Lohman, Vinod Francis Patel, Sreenivasarao Vepachedu, Yongping Xie
-
Patent number: 6660735Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: June 7, 2002Date of Patent: December 9, 2003Assignee: 3M Innovative Properties CompanyInventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
-
Patent number: 6656938Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: December 6, 2001Date of Patent: December 2, 2003Assignee: 3M Innovative Properties CompanyInventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
-
Patent number: 6653476Abstract: The present invention provides thienopyridine derivatives, which are useful as anti-inflammatory drugs, particularly as remedies for arthritis; processes for producing them, and pharmaceutical compositions containing them. The thienopyridine derivatives are represented by the formula (I): wherein G is a halogen atom, hydroxyl group, an optionally substituted amino group, etc.; alk is an optionally substituted lower alkylene group; X is O, S, —(CH2)q—, etc.; R is an optionally substituted amino group, etc.; ring B is an optionally substituted Y-containing 5- to 8-membered ring whose ring constituent atoms contain no nitrogen atom; Y is O, S, a group of (wherein Ra, Rb and Rc are the same or different and, each is H, a halogen atom, an optionally substituted hydrocarbon group, etc.), etc.; and ring A may be substituted.Type: GrantFiled: August 22, 2002Date of Patent: November 25, 2003Assignee: Takeda Chemical Industries, Ltd.Inventors: Tsuneo Yasuma, Atsuo Baba, Haruhiko Makino, Isao Aoki, Toshiaki Nagata
-
Patent number: 6653304Abstract: Use of a compound for treating a respiratory disease in a mammal wherein the compound is a cannabinoid receptor modulator is disclosed. Compounds useful as cannabinoid receptor modulators for treating respiratory and non-respiratory leukocyte-activation associated diseases comprise compounds of formula (I), in which A and B are nitrogen or carbon, provided only one of A and B is nitrogen; and R1-R6 are as defined in the specification, wherein R2 with R5 may form a ring, and/or two R4 groups may form a six-membered aryl or heteroaryl ring, optionally having a substituent R6 forming a ring with R3.Type: GrantFiled: February 8, 2001Date of Patent: November 25, 2003Assignee: Bristol-Myers Squibb Co.Inventors: Katerina Leftheris, Hong Wu, Stephen Wrobleski, Ping Chen, John Hynes, John Tokarski
-
Publication number: 20030212270Abstract: 1-substituted, 2-substituted 1H-imidazo[4,5-c]-quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce biosynthesis of interferon, and they inhibit tumor formation in animal models. This invention also provides intermediates for preparing such compounds, pharmaceutical compositions containing such compounds, and pharmacological methods of using such compounds.Type: ApplicationFiled: May 13, 2003Publication date: November 13, 2003Applicant: 3M Innovative Properties CompanyInventors: John F. Gerster, Kyle J. Lindstrom
-
Publication number: 20030207908Abstract: The present invention relates to optically pure S-(−)-benzoquinolizlne carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(−)-benzoquinoluzie carboylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantlly free of their R-(+)-isomers, and to pharmaceutical compositions comprising the S(+)-benzoquinolizie carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof.Type: ApplicationFiled: May 8, 2000Publication date: November 6, 2003Inventors: Mahesh Vithalbhai Patel, Shivkumar Agarwal, Sreenivas Kandepu, Nitin Shetty, Dilip Jatashankar Upadhyay, Nishith Chandra Chaturvedi, Abraham Thomas, Noel John De Souza, Habil Fakhruddin Khorakiwala
-
Patent number: 6638929Abstract: This invention provides compounds of formula 1, having the structure which are useful as inhibitors of protein tyrosine kinase and are antiproliferative agents.Type: GrantFiled: December 29, 2000Date of Patent: October 28, 2003Assignee: WyethInventors: Dan M. Berger, Minu D. Dutia, Frenel F. DeMorin, Diane H. Boschelli, Dennis W. Powell, Hwei-Ru Tsou, Allan Wissner, Nan Zhang, Fei Ye, Biqi Wu
-
Patent number: 6635638Abstract: The invention relates to novel pyrrolopyridinone derivatives of the formula (I) or (II): pharmaceutical compositions containing the compounds and their use for the treatment of sexual dysfunction.Type: GrantFiled: May 2, 2001Date of Patent: October 21, 2003Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Zhihua Sui, Mark J. Macielag, Jihua Guan, Weiqin Jiang, James C. Lanter
-
Publication number: 20030195189Abstract: Oxindole derivatives, specifically pyrrolo[3,2-f]quinoline-2-ones, which are useful as CDK4 inhibitors are described herein. The described invention also includes methods of making such oxindole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.Type: ApplicationFiled: February 27, 2003Publication date: October 16, 2003Inventors: Scott Howard Dickerson, David Harold Drewry, James A. Linn
-
Patent number: 6630467Abstract: Pyridone-fused azabicyclic compounds of the formula and their pharmaceutically acceptable salts and prodrugs, wherein R1, R2 and R3 are defined below, intermediates and methods for their preparation. Compositions and methods for using compounds of the formula I in the treatment of neurological and mental disorders related to a decrease in cholinergic function such as nicotine addiction, Huntington's Chorea, tardive dyskinesia, hyperkinesia, mania, dyslexia, schizophrenia, analgesia, attention deficit disorder (ADD), multi-infarct demetia, age related cognitive decline, epilepsy, neurological and mental disorders related to a decrease in cholinergic function, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), anxiety, obesity, Tourette's Syndrome and ulcerative colitis.Type: GrantFiled: February 14, 2001Date of Patent: October 7, 2003Assignee: Pfizer Inc.Inventor: Brian T. O'Neill
-
Patent number: 6627637Abstract: The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I&kgr;B kinase is involved.Type: GrantFiled: March 15, 2001Date of Patent: September 30, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne W. Hancock, Hormoz Mazdiyashi, Vito Palombella, Julian Adams
-
Patent number: 6624159Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.Type: GrantFiled: June 22, 2001Date of Patent: September 23, 2003Assignee: Pharmacia & Upjohn CompanyInventors: David John Anderson, Gordon L. Bundy, Fred L. Ciske, David R. Graber, Michael J. Genin, Thomas M. Judge, Malcolm Wilson Moon, Mark E. Schnute, Joseph Walter Strohbach, Suvit Thaisrivongs, Atli Thorarensen, Steven Ronald Turner, Valerie A. Vaillancourt, Allison J. Wolf
-
Publication number: 20030171369Abstract: Quinolylpropylpiperidine derivatives of general formula (I) are described, and are useful as antimicrobial agents. Their preparation is also described.Type: ApplicationFiled: March 14, 2003Publication date: September 11, 2003Applicant: Aventis Pharma S.A.Inventors: Eric Bacque, Serge Mignani, Jean-Luc Malleron, Michel Tabart, Michael Evers, Fabrice Viviani, Youssef El Ahmad, Stephane Mutti
-
Publication number: 20030166929Abstract: Disclosed are novel compounds of formula (I): 1Type: ApplicationFiled: November 12, 2002Publication date: September 4, 2003Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Roger John Snow, Mario G. Cardozo, Daniel R. Goldberg, Abdelhakim Hammach, Tina M. Morwick, Neil Moss, Usha R. Patel, Anthony S. Prokopowicz, Hindenori Takahashi, Matt Aaron Tschantz, Xiao-Jun Wang
-
Patent number: 6610319Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.Type: GrantFiled: December 19, 2000Date of Patent: August 26, 2003Assignee: 3M Innovative Properties CompanyInventors: Mark A. Tomai, David M. Hammerbeck, Karl F. Swingle
-
Publication number: 20030158193Abstract: Compounds of the formula 1 1Type: ApplicationFiled: September 27, 2002Publication date: August 21, 2003Inventors: J?ouml;rg Senn-Bilfinger, Wilm Buhr
-
Publication number: 20030158192Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: ApplicationFiled: December 6, 2001Publication date: August 21, 2003Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
-
Publication number: 20030158191Abstract: The invention provides cannabinol derivatives and pharmaceutical preparations thereof.Type: ApplicationFiled: December 22, 2002Publication date: August 21, 2003Inventor: Craig R. Travis
-
Patent number: 6608078Abstract: The present invention relates to optically pure 8-(substituted piperidino)-benzo[i,j]quinolizines, their isomers, derivatives, salts, pseudopolymorphs, polymorphs prodrugs and hydrates thereof, to processes for their preparation, and to pharmaceutical compositions comprising 8-(substituted piperidino)-benzo[i,j]quinolizines their isomers, derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof. These compounds and compositions possess potent activity in treating local and systemic infections, particularly infections caused by sensitive and resistant Gram-positive organism infections, Gram-negative organism infections, mycobacterial infections and nosocomial pathogens, and particularly those belonging to the staphylococcus, streptococcus and enterococcus groups. Methods for treating the diseases and disorders arising from the foregoing infections in humans and animals are described by administering the compounds of the invention to said humans and animals.Type: GrantFiled: May 7, 2001Date of Patent: August 19, 2003Assignee: Wockhardt LimitedInventors: Noel John De Souza, Mahesh Vithalbhai Patel, Shiv Kumar Agarwal, Shirkant V Gupte, Dilip J Upadhyay, Satish B Bhawsar, Mohammad A Jafri
-
Patent number: 6608057Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases.Type: GrantFiled: October 24, 2001Date of Patent: August 19, 2003Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Charles L. Cywin, Michel J. Emmanuel, Tina Morwick, Denice M. Spero, David S. Thomson, Yancey D. Ward
-
Patent number: 6608201Abstract: Methods of preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines are disclosed. The compounds function as antiviral agents, they induce the biosynthesis of various cytokines including interferon, and they inhibit tumor formation in animal models.Type: GrantFiled: September 10, 2002Date of Patent: August 19, 2003Assignee: 3M Innovative Properties CompanyInventors: John F. Gerster, Kyle J. Lindstrom
-
Publication number: 20030153561Abstract: The present invention provides a compound of formula I 1Type: ApplicationFiled: November 5, 2002Publication date: August 14, 2003Inventors: Valerie A. Vaillancourt, Sandra Staley, Audris Huang, Richard Allen Nugent, Ke Chen, Sajiv K. Nair, James A. Nieman, Joseph Walter Strohbach
-
Patent number: RE38452Abstract: Tricyclic nitrogen containing compounds, having anxiolytic and anti-depressant activity and central nervous system activity of the following structural formula: and pharmaceutically acceptable salts thereof wherein R1 and R2 are independently hydrogen, C1-6 alkyl or R1 and R2 are joined to form pyrrolidine, piperidine, morpholine or imidazole. X is OCH3, SO2R3, SO2CF3 or CN where R3 is C1-6 alkyl or an Aryl; and Y is hydrogen, Cl, Br, F, CN, CONR1R2, CF3, OCH3, SO2NR1R2. These new compounds are suitable for treating anxiolytic disorder, schizophrenia, Parkinson's disease, anxiety, depression or as compounds for lowering blood pressure or treating migraine headaches in patients in need of such treatment.Type: GrantFiled: May 13, 1999Date of Patent: March 2, 2004Assignee: Pharmacia & Upjohn CompanyInventor: Arthur Glenn Romero